EGFR and non-small cell lung carcinoma: The median survival time of patients with metastatic NSCLC to the brain with tumoral EGFR mutations is more favorable at the range of 19–26 months, likely as a reflection of the favorable predictive and prognostic indices for EGFR mutations per se (Jiang et al. 2016; Luo et al. 2014; Welsh et al. 2013).